GHK-Cu Peptide

GHK-Cu is three amino acids, first found in human blood in 1973, permanently holding a copper ion.

GHK-Cu peptide is the tripeptide glycyl-L-histidyl-L-lysine bound to copper. It was first isolated from human plasma in 1973 and is listed in cosmetics as copper tripeptide-1. Researchers study it in wound and skin-matrix work because copper is a cofactor for lysyl oxidase. Its controlled human trials used topical formulations. It isn't approved as a drug in Canada or anywhere else.

Most compounds on this shelf got invented. This one got found, floating around in human plasma like it owned the place, back when Loren Pickart was looking at what made old liver cells act young in a dish.

Glycine, histidine, lysine, plus a copper ion it holds onto so tightly the copper made it into the name.

Stay with me on the copper. Think of GHK as a delivery driver and the copper as the pizza, except the driver's legally married to the pizza. Plasma levels drop as you age, which handed the skincare aisle its favourite sentence, and forty years of copper peptide creams got built on top of that one line.

Underneath the creams there's real chemistry. A genuine copper-binding motif, with a real job in the enzyme that builds skin's scaffolding. That part isn't marketing.

A real molecule with a real decline curve, and an industry parked in the gap between those two facts and proof. The research section keeps score.

Copper isn't decoration in here. It's a working part.

Lysyl oxidase, the enzyme that rivets collagen and elastin into scaffolding, needs a copper atom to run at all. No copper, no rivets, and the scaffolding's a pile of loose rebar.

The GHK motif grips copper hard, and the proposed job is courier work: peptide carries the ion, the enzyme gets its copper, the scaffolding work carries on.

There's also cell-culture work on gene expression that the forums quote like scripture. It's real. It's also cells in a dish.

We're not gonna dress it up. What a plausible courier does in a dish and what it does in your skin are two different questions, and only one of them has been tested properly, roughly twice, in thirty years.

A courier with a good story, two real tests, and a split decision.

Forty years of cosmetic marketing sits on a remarkably small pile of controlled tests, and the two best ones don't agree with each other.

The 1994 trial (Mulder and colleagues, Wound Repair and Regeneration): a topical gel on foot ulcers caused by diabetic nerve damage, several hospitals, patients assigned at random, and judges who didn't know who got the real gel. Ulcers on the gel closed by a median of 98.5 percent against 60.8 for the plain gel. It's a wound result, not a wrinkle result.

Everything else is cell work, small open-label studies, and papers from people with a cream to sell. The gene-expression claims trace back to a 2018 review by the peptide's discoverer, and a review isn't a trial.

Even the news has caught up. NPR's headline on 7 September 2026: "The copper peptide trend has gone from creams to injections, ahead of the science."

Nothing approved as a drug anywhere. Not for skin. Not for wounds either, which surprises people.

Here's the honest part. One old win in wounds, one modern null in aesthetics, and an industry that only quotes the first. Both results are real, so both live on this page.

You'll read the 1994 number on forty other sites. You'll read the 2006 one here, with the link.

Route is the whole question. The evidence for this compound is topical. In May 2026 the FDA let every form of GHK-Cu back onto the list compounding pharmacies may work from, except the injectable ones, and said the human data for that route are limited. Health Canada hasn't approved it as a drug in any form.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.